Research and Markets: 2011 Trends to Watch: Pharmaceutical Technology

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/ed49de/2011_trends_to_wat) has announced the addition of the "2011 Trends to Watch: Pharmaceutical Technology" report to their offering.

In collaboration with analysts from Datamonitor's Healthcare business unit, in this brief Ovum's Pharmaceutical Technology team outlines the key changes in the pharma industry, explains which trends will have the biggest impact, and analyzes the implications and opportunities of these developments for both pharmaceutical companies and providers of technologies and services.

Features and benefits:

Gives an overview of the current landscape for the global pharmaceutical and biotechnology industries
Offers insight into factors driving the life sciences industry's need for IT and how vendors can help companies overcome market challenges
Provides strategies to help technology vendors penetrate the life science industry

Highlights;

2011 will be a challenging year for the life sciences industry as a result of the dreaded patent cliff, an increase in drug pricing pressures and heightened regulatory scrutiny on drug safety and pharma's marketing tactics. In response to declining sales and rising R&D costs, the industry is expanding out of the developed markets of US, Europe and Japan, into the emerging markets, particularly China and India. Experiencing tremendous growth already, these emerging markets will not be emerging much longer. 2011 brings with it many challenges and opportunities for the life sciences industry, and while several uncertainties remain, one thing is certain: technology will be integral to those hoping to see 2012.

Your key questions answered;

Learn about the top trends in the life science industry in 2011
Tailor your go-to-market strategy to address critical issues facing pharmaceutical and biotechnology companies
Identify strategies for expanding business opportunities in the life science industry

Key Topics Covered:

BUSINESS TRENDS AND TECHNOLOGY ENABLERS

Several key trends and enablers will influence the life sciences industry in 2011

THE 2011 PATENT CLIFF, DRUG PRICING PRESSURES, AND INCREASED REGULATIONS RESTRICT PHARMA'S GROWTH

The long-dreaded patent cliff of 2011 is finally here
Bad news for branded pharma means good news for generics companies
Surviving the patent cliff requires pharma to have a new innovative vision of CRM
The US health reform, in conjunction with a global healthcare crisis, will escalate drug pricing pressures in 2011
To curb skyrocketing healthcare costs, payers are invoking price cuts and reimbursement restrictions
The right social media strategy can do wonders for a pharma company's reputation
Continued regulatory scrutiny is impacting pharma's everyday way of life
Consumer knowledge will significantly affect pharmacovigilance activities

THE EMERGING MARKETS WILL NOT BE EMERGING MUCH LONGER

With an average CAGR of 12% over the next two years, the burgeoning emerging pharma markets are attractive, but some pitfalls remain
Partnering with a domestic firm is the best way for a multinational company to enter an emerging market
With cost-cutting in mind, outsourcing will continue to increase
CROs will have a significant impact on the transformation of the R&D landscape
Emerging markets are hotspots for outsourcing pharma R&D and manufacturing
IT investment will be essential for growth in the emerging markets
Asia and Russia offer the greatest short- and long-term opportunities for IT vendors
Pharma-specific technology solutions will be crucial to growth
With the Latin American markets starting to boom, IT investment will soon follow
The potential of cloud computing to scale quickly

AS R&D PRIORITIES CHANGE, THE LINE BETWEEN PHARMA AND BIOTECH WILL BLUR EVEN MORE IN 2011

The biotech sector is set to play a greater role in the future of the life sciences industry
Secondary care indications and niche patient populations will drive new drug R&D and sales growth
The high costs of developing a blockbuster drug push pharma towards alternatives
Biotechnology will fuel personalized medicine, but the dream is still a way off
Barriers must be overcome before the potential of personalized medicine is realized
The new R&D model will require the integration of IT into drug discovery

RECOMMENDATIONS